Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497578 | 0.84 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL23100773 | 0.73 | — | — | |
| SCHEMBL8766370 | 0.68 | PNMT (0.35) | CA1CA2 | |
| SCHEMBL31513999 | 0.68 | CYP1A2 (0.35) | — | |
| SCHEMBL31513977 | 0.68 | HTR2C (0.38) | — | |
| SCHEMBL4856868 | 0.68 | CYP1A2 (0.35) | — | |
| SCHEMBL1896564 | 0.68 | HTR2C (0.38) | — | |
| SCHEMBL1478133 | 0.68 | PNMT (0.35) | — | |
| SCHEMBL34474640 | 0.68 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL2008802 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106855-B1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | NISSAN CHEMICAL IND LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-7851503-B2 | Thrombopoetin receptor activator and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-14 | — | — | US | disclosed |
| US-7700789-B2 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| EP-1632291-B1 | HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST | NISSAN CHEMICAL IND LTD (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2106855-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | Nissan Chemical Industries, Ltd. (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-20090082583-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20070093667-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1632291-A1 | HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST | Nissan Chemical Industries, Ltd. (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20050282730-A1 | Thrombopoetin receptor activator and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1552828-A1 | THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME | Nissan Chemical Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093667-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | OXGR1, OXER1, OGFOD1 | CA1 181/4885CA2 232/4885 |
| US-20090082583-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | OXGR1, OGFOD1, OGDH | CA1 196/4885CA2 229/4885 |
| US-20050282730-A1 | Thrombopoetin receptor activator and process for producing the same | PDGFRA, PTAFR, TBXA2R | CA1 4458/4885CA2 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.